Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MRTTSE:6034 +0.34%62 Return-on-Tangible-Asset is 12.68% as of Jun. 2026, which is 149% above its 10-year median of 5.10. GuruFocus rates TSE:6034 with a GF Score™ of 62/100 and a GF Value™ of 円605.70 (Fairly Valued). The stock has 4 warning signs investors should review. Among 687 Healthcare Providers & Services companies, MRT ranks worse than 56.91% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. MRT's annualizedNet Income for the quarter that ended in Jun. 2026 was 円722 Mil. MRT's average total tangible assets for the quarter that ended in Jun. 2026 was 円0 Mil. Therefore, MRT's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 12.68%.
The historical rank and industry rank for MRT's Return-on-Tangible-Asset or its related term are showing as below:
TSE:6034'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -5.2 Med: 5.1 Max: 36.29
Current: 1.46
During the past 13 years, MRT's highest Return-on-Tangible-Asset was 36.29%. The lowest was -5.20%. And the median was 5.10%.
TSE:6034's Return-on-Tangible-Asset is ranked worse than 56.91% of 687
companies
in the Healthcare Providers & Services industry
Industry Median: 2.59
vs TSE:6034: 1.46
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
MRT Return-on-Tangible-Asset Related Terms
MRT Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for MRT's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6034 vs HCA, THC, EHC: Return-on-Tangible-Asset Comparison
For the Medical Care Facilities subindustry, MRT's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MRT Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MRT's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where MRT's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 12.68% mean?
MRT (TSE:6034) has a Return-on-Tangible-Asset of 12.68% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on MRT and its competitors. This is 149% above median its historical median of 5.10. According to the industry distribution chart, MRT ranks #391 out of 687 companies in the Healthcare Providers & Services industry, placing it in the top 56.9%.
Is MRT's Return-on-Tangible-Asset too high?
MRT's current Return-on-Tangible-Asset of 12.68% is 149% above median its 10-year median of 5.10. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.59. MRT's value of 12.68% is 389.6% above this industry median. Based on the distribution chart, MRT ranks #391 out of 687 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, MRT has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MRT's Return-on-Tangible-Asset compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, MRT ranks #391 out of 687 companies for Return-on-Tangible-Asset. This places MRT in the lower half of its industry. The industry median Return-on-Tangible-Asset is 2.59. MRT's value of 12.68% is 389.6% above this benchmark. While the company's 10-year median is 5.10 vs. the industry median of 2.59, MRT has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.59, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MRT's current Return-on-Tangible-Asset of 12.68% is 389.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on MRT and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MRT's current Return-on-Tangible-Asset is 12.68%, which is 149% above median its own 10-year median of 5.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MRT stock overvalued right now?
Based on GuruFocus' analysis, MRT (TSE:6034) is currently considered Fairly Valued. The stock's GF Value™ is 円605.70, compared to a current price of 円588.00 — trading 2.9% below its estimated fair value. The current Return-on-Tangible-Asset is 12.68%, which is 149% above median its 10-year median of 5.10 and 389.6% above the Healthcare Providers & Services industry median of 2.59. MRT's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For MRT (TSE:6034), the current Return-on-Tangible-Asset is 12.68% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MRT (TSE:6034) Overvalued in 2026?
Based on GuruFocus' analysis, MRT stock appears to be undervalued.
The current stock price of 円588.00 is trading 2.9% below its estimated GF Value™ of 円605.70.
GuruFocus considers MRT to be Fairly Valued.
Key valuation signals for TSE:6034:
Return-on-Tangible-Asset: 12.68% (149% above median its 10-year median of 5.10)
GF Value™: 円605.70 vs. price of 円588.00 (2.9% below fair value)
Industry Position: 389.6% above the Healthcare Providers & Services median (#391 of 687)
No single metric tells the full story. See the TSE:6034 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MRT Inc engages in the business of medical personnel placement services through the Internet. It provides part-time and full-time physician referral services through the physician referral site, as well as part-time job referral, job change introduction services to nurses, pharmacists, clinical laboratory technicians, clinical engineers, and radiologists. Further, the company engages in the research and development of analytical and analytical methods for various biological samples, such as microorganisms, blood, proteins, and genes; and research and development, manufacture, and sale of medical and medical examination equipment, and analytical instruments.
62GF Score
Get the complete analysis for TSE:6034
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6034 has been successfully added to your 
